The Wilms' tumour suppressor gene, WT1, encodes multiple nuclear protein isoforms, all containing four C-terminal zinc ®nger motifs. WT1 proteins can both activate and repress putative target genes in vitro, although the in vivo relevance of these putative target genes is often unveri®ed. WT1 mutations can result in Wilms' tumour and the Denys-Drash Syndrome (DDS) of infantile nephropathy, XY pseudohermaphroditism and predisposition to Wilms' tumour. We have established stable transfectants of the mouse mesonephric cell line, M15, which express WT1 harbouring a common DDS point mutation (R394W). A comparison of the expression pro®les of M15 and transfectant C2A was performed using Nylon-based arrays. Very few genes showed dierential expression. However Wnt-4, a member of the Wnt gene family of secreted glycoproteins, was downregulated in C2A and other similar clones. Doxycycline induction of WT1-A or WT1-D expression in HEK293 stable transfectants also elicited an elevation in Wnt4 expression. Wnt4 is critical for the mesenchyme-to-epithelial transition during kidney development, making it an attractive putative WT1 target. We have mapped human Wnt-4 gene to chromosome 1p35-36, a region of frequent LOH in WT, have characterized the genomic structure of the human Wnt-4 gene and isolated 9 kb of immediate promoter. While several potential WT1 binding sites exist within this promoter, reporter analysis does not strongly support the direct regulation of Wnt4 by WT1. We propose that Wnt-4 regulation by WT1 occurs at a more distant promoter or enhancer site, or is indirect.
Introduction
Wilms' tumour (WT) or nephroblastoma is an embryonal renal neoplasm aecting one out of 10 000 infants, thus accounting for about 6% of all childhood malignancies (Matsunaga, 1981) . The tumour characteristically displays a triphasic histology consisting of undierentiated blastemal stem cells, an epithelial component, and ®broblastic stromal elements (Miller et al., 1964) . It is thought to arise from metanephric blastemal cells that failed to properly dierentiate into the epithelial components of the kidney, possibly due to the inability of blastemal stem cells to respond to normal dierentiation signals (Miller et al., 1964) . WT can occur in association with other congenital anomalies, one of which is the WAGR syndrome of Wilms' tumour, Aniridia (lack or defect of the iris), Genitourinary anomalies, and mental Retardation. The detection of cytogenetically detectable microdeletions at chromosome position 11p13 in WAGR patients (Francke et al., 1979) facilitated the positional cloning of the WT suppressor gene, WT1 (Call et al., 1990; Gessler et al., 1990) . While numerous inactivating mutations have been found in this gene in WT, the percentage of WT cases with WT1 mutations is only 10 ± 15% (Little and Wells, 1997) . WT show regions of LOH at 11p13, but also on many other chromosomes, including chromosomes 1p, 1q, 7p, 16q, and 17p (Slater and Mannens, 1992) . It is possible that these loci represent other WT genes, which may lie up or downstream of WT1. Constitutional heterozygous WT1 mutations are also found in the congenital anomaly of Denys-Drash syndrome (DDS) (XY pseudohermaphroditism, mesangial sclerosis, and predisposition to WT1) . The most common of these, C1180T, occurs within exon 9 of WT1 resulting in the substitution of arginine by tryptophan (R394W) (Little and Wells, 1997) .
The WT1 gene encodes multiple nuclear proteins by virtue of three dierent transcription start sites, RNA editing of a single nucleotide and two alternatively spliced regions; exon 5 (17 amino acids) and an alternate splice donor site after exon 9 Sharma et al., 1994; Bruening and Pelletier, 1996; Scharnhorst et al., 1999) . The latter results in the addition of three amino acids (KTS) between exons 9 and 10. All isoforms contain the four C-terminal zinc ®ngers. Taking the alternate splice sites into account and using the most common start site, four isoforms of 52 ± 54 kD have been described as WT1-A (7exon 5/7KTS), WT1-B (+/7), WT1-C (7/+) and WT1-D (+/+) . The ratio of these isoforms remains stable spatially and temporally, suggesting all are needed simultaneously and may interact with each other . Indeed, all WT1 isoforms can self-associate via two regions within their N-terminal ends . WT1 protein can bind DNA via its zinc ®ngers. WT1-KTS shows highest speci®city for the early growth response gene (EGR1) consensus binding site (Madden et al., 1991) . Based on this and EGR1/WT1 chimeric protein analyses, WT1 has been thought to act by repressing the expression of growth-inducing genes and most putative target genes are repressed by WT1 in vitro. The putative target genes described in the literature include other transcription factors (Pax2, EGR1, c-myc, c-myb, MyoD, WT1, Dax1), growth factors (IGF2, PDGF-A, CSF-1, CTGF, amphiregulin, inhibin a, TGFb1, midkine), growth factor receptors (EGFR, IR, IGF1R, RARa), extracellular matrix genes (syndecan), cell survival genes (Bcl-2), signalling molecules (Gai-2) and other genes (novH, ODC, hTERT, thrombospondin, Ecadherin) (Dejong et al., 1999; Hosono et al., 1999; Kim et al., 1999; Lee et al., 1999; reviewed in Little et al., 1999; Oh et al., 1999; Stanhope-Baker and Williams, 2000) . While in vitro techniques such as EMSA and luciferase reporter assays have supported the candidacy of many of these putative WT1 target genes, interpretation of this data is dicult due to the discrepancies in experimental results when parameters such as cell line, expression vector, WT1 isoforms expressed and promoter architecture of the putative targets was varied (Reddy and Licht, 1996) . Veri®cation of the in vivo relevance of previously reported WT1 target genes remains incomplete and further investigation of the role of these genes in kidney development is required.
More recently, cell lines overexpressing wildtype WT1 isoforms have been established and screened for changes in gene expression in a variety of ways. Englert et al. (1997) investigated the eect of WT1 by creating Saos2 and U2OS osteosarcoma cell lines inducibly expressing WT1 isoforms in response to tetracycline (Gossen et al., 1995) . They proposed that WT1 induction triggered apoptosis and transcriptionally repressed the epidermal growth factor receptor (EGFR) gene. The apoptosis observed was thought to be initiated in part by induction of p21. No other putative WT1 target genes were aected. Hosono et al. (1999) created stable WT1-expressing transfectants of the Rastransformed NIH3T3 cell line, which they investigated for changes in markers of epithelialization, including Ecadherin, uvomorulin and collagen IV. They concluded that induction of WT1 stimulated epithelialization of this cell line and decreased tumorigenicity. Thate et al. (1998) utilized human embryonal kidney (HEK293), Wilms tumour (G401) and osteosarcoma (Saos2) cell lines inducibly expressing WT1 in response to tetracycline to screen using dierential display (DD ± PCR). They failed to detect any dierentially displayed PCR product that withstood veri®cation by Northern analysis and concluded that either WT1 only regulates a very small set of genes undetected using DD ± PCR or that WT1 may not act as a transcription factor that in¯uences steady state levels of mRNA (Thate et al., 1998) . Using oligonucleotide arrays (Aymetrix), Lee et al. (1999) performed another screen of 6800 human transcript sequences for target genes. This again used the tetracycline inducible U2OS cell lines of Englert et al. (1997) inducing either +KTS or 7KTS isoforms. Induction of WT1-KTS resulted in the 74-fold upregulation of amphiregulin, a member of the epidermal growth factor family. This ligand, subsequently shown to be co-expressed with WT1 during kidney development, can both induce proliferation in some epithelial cells and inhibit the growth of many cancer cell lines (Shoyab et al., 1988) . Importantly, no previously described WT1 target genes were found to be reproducibly repressed following expression of WT1(7KTS) and induction of WT1(+KTS).
The relevance of some of these cell-line approaches is unclear given the likely modulation of WT1 action by kidney speci®c factors and the inappropriateness of overexpressing a single WT1 isoform at a time. Although successful at isolating amphiregulin, a gene involved in kidney development, from an osteosarcoma cell line induced to express WT1 (Lee et al., 1999) , other kidney-speci®c genes may have been missed. In this study, we have performed a limited screen for in vivo WT1 gene targets via comparative analysis of endogenous gene expression pro®le between two cell lines; an endogenous WT1 expressor and a cell line mutant for WT1. We used the parental SV40-transformed mouse mesonephric cell line M15 (Larsson et al., 1995) as this cell line expresses all WT1 isoforms and is likely to also be producing other proteins required for WT1 function. Stable transfectants that persistently express a DDS mutant (R394W point mutation) form of WT1-C were generated from parental M15 cells. Expression analyses were performed using the mouse Atlas array (http://www.clontech.com/, mouse Atlas, 588 known murine genes) and our own 96-gene nylon array. The latter was created with the aim of rapidly verifying or eliminating previously proposed WT1 target genes and screening a set of known genes known to be involved in kidney development, apoptosis or leukemia. Our results fail to validate any of the previously proposed WT1 target genes but do demonstrate that Wnt-4 expression levels decrease in the presence of a dominant-negative WT1 protein, implying that WT1 may normally positively regulate Wnt4 during kidney development.
Results

M15 transfectants express the WT1 mutation (R394W) transgene
The M15 cell line is a murine embryonic kidney (mesonephros-derived) cell line that endogenously expresses WT1 (Larsson et al., 1995) . Parental M15 was co-transfected with the mammalian expression constructs pEF ± DM and pgk-NEO. pEF ± DM expresses WT1-C isoform containing a C1180T mutation within exon 9 which results in an arginine to tryptophan substitution in zinc ®nger 3 (Figure 1a ). This mutation represents the most commonly occurring WT1 mutation in DDS (Little and Wells, 1997) . The DNA binding ability of the resultant mutant protein is severely impaired (Little et al., 1995) , however such mutations appear to be able to act in a dominant-negative fashion possibly via their continued ability to interact with wildtype WT1 via the N-terminal self association domains . G418-resistant stable transfectants of M15 were screened using RT ± PCR SNuPE (Singer-Sam et al., 1992) to verify the expression of the mutant WT1. Six transfectants expressed the mutant WT1 transcript, with clones C2A and C5B showing the highest expression levels (Figure 1b, c) . Throughout this study regular SNuPE assays were used to verify the stability of these clones ( Figure 1c ). Initial RT ± PCR was also performed to validate the SnuPE assay results. All transfectants positive in the SnuPE were shown to be expressing both wildtype and mutant WT1 transcripts (Figure 1d ). The growth rate of C2A and C5B was compared with M15. Both C2A and C5B appeared to grow more slowly and plateau at a lower cell number than parental M15 (Figure 1e ). Annexin immunouorescence was performed to determine whether there was a greater rate of apoptosis occurring in these cells but this did not appear to be the case (data not shown). It was not possible to determine the eciency with which the mutant transcript was translated as only a single amino acid has been altered. However, our previous experience with the generation of a mouse model of DDS using a truncation mutation would suggest that the mutant protein is produced (Patek et al., 1999) . In addition, Western blotting and immuno¯uorescence were performed on C2A and C5B, revealing an increase in protein production of approximately twofold (Figure 1f ).
Array analysis revealed few differentially expressed genes between M15 and C2A
To perform comparative gene expression analysis between M15 and the stable transfectant, C2A, we used a custom made nylon-based array comprising 96 dierent genes (http://www.cmcb.uq.edu.au/pubs/ array.html). The latter comprised genes either previously reported as putative WT1 targets or genes relevant to some aspect of WT biology spatially clustered into the subgroups of transcription factors, growth factors, growth factor receptors, cell cycle genes, extracellular matrix or cytoskeletal genes, miscellaneous genes, and control housekeeping genes (Figure 2a,b) . Genomic DNA controls were also included. As some of the cDNA clones on this array were human genes, we also utilized the commercial mouse Atlas TM array, which contains 588 known mouse ESTs (Clontech) (Figure 3a) . Radioactivelylabelled cDNA probes from M15 and C2A mRNA populations were synthesized and checked for comparable a 32 P-incorporation prior to hybridization. After normalization for ribosomal S29 expression between M15 and C2A, a total of eight genes on the Clontech array showed dierential expression of at least twofold (Figure 3a,b) . Transcription termination factor (TTF-1) (C2A/M15 ratio=4.9), p18-ink4c (2.5), glutathione S-transferase (2.32) and non-muscle myosin light chain 3 (2.68) were upregulated in C2A, while prothymosin (0.48), ERp72 (0.11), glutathione reductase (0.18) and HSP84 (0.49) were downregulated in C2A (Figure 3b) . Veri®cation was performed for three of these genes, TTF-1, glutathione S-transferase and HSP84 using EST clones to distinct regions of the same genes (BG072544, BG086330 and BG079631 respectively). TTF-1 was seen to be expressed in C2A (Figure 3c ), but not other clones. The murine TTF-1 gene is required for the termination of mouse ribosomal gene transcription by RNA polymerase 1 (Evers et al., 1995) . Neither glutathione S-transferase nor HSP84 demonstrated dierential expression between parental M15 and WT1 mutant clones C2A, C5B and C1B.
Using the WT1 target gene array, only 12 of 94 genes present were detected (Figure 2b ,e). In comparison to M15, the c-myc, NUP98 and fos-B genes were up-regulated by greater than twofold in C2A while cyclin E and Wnt-4 were down-regulated on the Wilms' tumour array. To verify the observed results in terms of gene speci®city and relative levels of expression, Northern analysis was performed using both the cyclin E and Wnt4 cDNAs. Cyclin E downregulation was not veri®ed when multiple passages and transfectants were examined, nor was it con®rmed by the Clontech array hybridization. Northern analysis revealed the two anticipated murine Wnt4 RNA transcripts (1.6 and 4.7 kb) (Gavin et al., 1990) in M15 cells, less in C2A and none in 10t1/2 cells (negative control) ( Figure 2c ). To con®rm that the downregulation of Wnt-4 in C2A was not simply due to clonal variation between C2A and parental M15, another passage of C2A and a second stable transfectant were tested for their level of Wnt4 expression and quantitated via phosphoimaging ( Figure 2d ). This demonstrated a much less signi®cant (1.6 and twofold in C2A and C5B respectively) but nevertheless consistent downregulation of Wnt4 expression. Loading control was comparable, as checked by hybridization of the membrane with 18S rRNA (Figure 2d ). The relative expression of all genes detectable on the Wilms' tumour array is shown in Figure 2e .
hWnt-4 maps to human chromosomal position 1p35.1-36.23
To characterize the hWnt-4 gene, the full length cDNA sequences of mouse Wnt-4 were screened for matches to human DNA sequences. This was done using Basic 
BLAST (BlastN) algorithm searches against the nonredundant GenBank database of NCBI and resulted in the identi®cation of eight human ESTs that were highly similar to the mouse Wnt-4 cDNA (AL139742, AL634496, AL632967, AL267902, AL634480, AA934393, H23429, and AA434160). A consensus sequence of a partial putative human Wnt4 ORF was derived by creating a contig of these ESTs. This composite putative hWnt-4 cDNA was again subjected to BlastN analysis and found to match (499% homology) regions within the Clone 224A6 (GenBank accession no. AL031281.6). Clone 224A6 is a 129 kb human genomic clone derived from human chromosome 1p35.1-36.23 described as containing multiple ESTs, STSs, GSSs, the CDC42 gene and part of a gene similar to Mouse Wnt-4 protein. Comparisons between the virtual hWnt4 cDNA and the sequence of 224A6 allowed the genomic mapping of exon-intron boundaries from intron 1 to exon 5 (Figure 4 ). Sequences from exon 1 were not contained within Clone 224A6. The nucleotide identity between murine Wnt4 and this putative human Wnt4 cDNA is 90%. The genomic structure of the gene (5 exons) is also highly conserved between mouse and human.
Isolation of hWnt-4 exon 1 and 5' flanking DNA from a human PAC genomic clone To complete the genomic structure and isolate the hWnt4 promoter, we used a PCR strategy to screen for these regions from the RPC1 human PAC library (Ioannou et al., 1994) using PCR primers in putative hWnt4 intron 1. Of 28 clones screened, 11 single colonies proved positive for the expected intronic region. PAC clones 224 ± 1.1 and 289 ± 3.1 were selected for a second round of PCR-based PAC screening using primers speci®c for exon 1 of hWnt4. Only clone 289 ± 3.1 harboured hWnt4 exon 1, indicating that this clone extends furthest 5'. EcoRI and HindIII digests of 289 ± 3.1 were subjected to Southern analysis using a 63 bp exon 1 fragment. A 7 kb EcoRI and a 12 kb HindIII fragment containing exon 1 were subcloned and endsequenced using T7 and T3 primers facilitating the orientation of each with respect to intron 1. These were subsequently shotgun subcloned and sequenced to create a contig of the region (Figure 5a ). The entire 12 kb HindIII fragment of genomic DNA, including exon 1, was sequenced and submitted to GenBank as three linked submissions (Account number AY033055- These genes are TTF-1 (1), p18-ink4c (2), prothymosin alpha (3), HSP84 (4), ERp72 (5), glutathione reductase (6), microsomal glutathione-s-transferase (7), non muscle myosin light chain 3 (8). Arrowheads indicate the control genes ubiquitin (G5), b actin (G19), and ribosomal S29 (G21). (b) Bar graph indicating the relative levels of expression between M15 and C2A of those genes indicated in (a) as having a dierential expression of greater than twofold after normalization to ribosomal S29 expression. The C2A/M15 ratio is indicated above each. Numbers used are as in (a). (c) Northern blot analysis of microsomal glutathione-s-transferase, HSP84, and TTF-1 expression in parental M15 and three mutant WT1 derivative clones, C2A, C1B and C5A AY033057). The transcriptional start site was not characterized due to a lack of human Wnt4 expressing cell lines, but we presume due to the highly GC-rich nature of the genomic region close to the translational start site (Figure 5b ) and the existence of a short 5'UTR in mouse that most of this 9 kb region will represent immediate promoter. To determine what transcription factors (TF) may regulate Wnt4, MatInspector V2.2 (Quandt et al., 1995) was used to analyse 1.2 kb of immediate promoter for TF binding sites (Figure 5b ). The region was also searched for putative WT1 binding sites using a number of putative binding sites previously reported (see Materials and methods) (Figure 5b ). Four putative WT1 binding sites were identi®ed in this fashion; 5' GGGCGGGGG 3' (7754), 5' GTGGGGGGG 3' (7601); 5' GGGGGGGTG 3' (7329) and 5' CGCCCGCCCGCCCGCCC 3' (7255) (Figure 5a ). Of note was the presence of a potential Sry-binding site (5' CAAACAAGAGG 3') at 71133. This is interesting considering the proposed role of Wnt4 in female development (Vainio et al., 1999) .
Reporter assays were then used to determine whether any WT1 isoforms could activate Wnt4 reporter activity in vitro. In both COS7 and M15 cells, this region appeared to be able to act as a minimal promoter, showing considerably higher activity than the pGL-Basic construct. Using this 1.2 kb immediate promoter, a mild but consistent activation of luciferase activity was observed with each WT1 isoform, but more so with WT1-C, in both COS and M15 cells. However, the WT1-DM construct had a similar eect. Similar reporter assays using the entire 9.0 kb of the Wnt promoter (Wnt4p9.0) suggested no transcriptional activation at all by any WT1 isoform (data not shown). To further investigate the mild activation of this minimal Wnt4 promoter by WT1, tetracyclineinducible WT1-A and WT1-D expressing HEK293 cells were transfected with the 1.2 kb promoter with and without doxycycline induction of WT1 production ( Figure 6c ). The 1.2 kb minimal promoter again appeared to be acting as a minimal promoter when compared to the pGL-Basic control. After 24 h of WT1 induction, there was mild repression of luciferase activity, whereas after 48 h there was no change (Figure 6c ). However, Northern analysis of a timecourse of WT1 protein induction for both WT1-A and WT1-D suggested an initial repression of Wnt4 expression around 1 h post induction followed by a clear induction of Wnt4 expression by 48 h ( Figure  6d ). This was present in both WT1-A and WT1-D expressing cells, but more marked in the WT1-D expressing HEK293 cells (Figure 6d ). Coincident Western analysis would suggest that this may be due to a more rapid induction of WT1 protein in WT1-D expressing cells (Figure 6e ).
Discussion
The Wnt-4 gene encodes a member of the Wnt-gene family of secreted glycoproteins (Gavin et al., 1990) . During mouse metanephric kidney development, Wnt-4 expression is ®rst detected in the metanephric mesenchyme (MM) that condenses around the tip of the invading ureteric bud (UB). Wnt-4 expression continues during epithelialization of mesenchymal condensates into comma-and S-shaped bodies, and is ®nally lost when fusion of epithelial tubules to collecting ducts occurs (Stark et al., 1994) . Mice with a homozygous Wnt-4 null mutation (Wnt-4 7/7 ) die within 24 h of birth due to kidney failure (Stark et al., 1994) . All neonatal and 18.5 days post coitum (dpc) Wnt-4 7/7 embryos have agenic kidneys showing a small amount of undierentiated mesenchyme interspersed with branches of collecting duct epithelium (Stark et al., 1994) . Despite some degree of ureteric epithelium branching, the early mesenchymal condensates failed to form pretubular aggregates. This ablation of further development of any MM-derived structures suggested that expression of Wnt-4 is important for the process of MET during metanephric nephrogenesis. In these mice, early MET markers, including WT1, Pax2, and N-myc, remained unchanged until 14 dpc suggesting that Wnt-4 is downstream of these genes. WT1 is upregulated in expression at the point of the mesenchyme to epithelial transition (MET) (Pritchard-Jones et al., 1990) and the frequent observation of persistent blastema and unsuccessful attempts at epithelialization in Wilms' tumours implicate WT1 in the same MET. Despite this, Wnt4 has not previously been proposed to be regulated by WT1.
In an eort to unravel in vivo physiological targets of WT1 during metanephric kidney organogenesis, we have utilized a candidate gene array screening strategy to compare expression pro®les between M15 and a stable transfectant expressing a DDS mutant form of WT1 (R394W) in addition to endogenous WT1 isoforms. A total of 13 genes displayed dierential expression of greater than twofold, the greatest dierential being for cyclin E, TTF-1 and Wnt4. This was veri®ed by Northern analysis in the case of Wnt4, demonstrating that Wnt4 is expressed in M15 cell lines and that this expression is reduced in the presence of overexpression of a Drash mutant form of the protein. This implies some form of regulation of Wnt4 by WT1. As this analysis compared a parental cell line with a stable transfectant, it was quite possible that this eect was indirect.
To investigate further the relationship between WT1 and Wnt4, we have chromosomally localized human Wnt4, de®ned the human Wnt4 gene structure and characterized 9 kb of immediate promoter. Luciferase reporter assays were used to investigate whether WT1 regulated Wnt4 directly by controlling transcriptional regulation. The immediate 1.2 kb of Wnt4 promoter showed considerable activity in several cell lines in the absence of WT1, but was only mildly activated by all WT1 isoforms. Analysis of the eect of WT1 protein induction upon the activity of the 1.2 kb promoter did not suggest direct activation and yet these cell lines clearly showed an increase in Wnt4 message levels in response to WT1. Reporter assays using the entire 9 kb of the Wnt4 promoter showed no activity at all in any cell line examined. It is possible that WT1 does transcriptionally regulate Wnt4 from a site outside of this promoter region, possibly involving a remote enhancer element. Alternatively, the eect on Wnt4 message levels is either an indirect consequence of WT1 protein production or the regulation of Wnt4 by WT1 is post-transcriptional, aecting message stability or dierential processing.
Some Wnt genes can behave in an oncogenic fashion, as exempli®ed by Wnt1 (Christiansen et al., 1996) . While no Wnt gene mutations have been associated with Wilms' tumour and Wnt4 has never been reported to behave in this fashion, Koester and Ridder (1999) demonstrated that 15% (6 out of 40) of WTs, harbour heterozygous missense/microdeletion mutations in the b-catenin proto-oncogene. Induction of b-cateninmediated transcriptional regulation represents the end point of the Wnt signal transduction pathway (Nusse, 1999) . However, the mutations detected were activational mutations resulting in the accumulation of bcatenin protein within the tumours examined. This would argue that hyperactivation of the classical Wnt pathway is occurring in Wilms' tumour, rather than Wnt pathway disruption as our results might suggest. However, Wnt4 is one member of the Wnt gene family which can neither induce transformation in C57 cells nor induce the accumulation of b-catenin (Wong et al., 1994; Shimizu et al., 1997) . It is more consistent to propose a disruption to Wnt4 induction of kidney epithelialization than an overactivation of this event in the case of Wilms' tumour. Hence, the detection of bcatenin mutations in a subgroup of Wilms' tumours may suggest the disruption to the downstream pathway of another member of the Wnt gene family. Wnts 4, 5B, 7B and 11 are all expressed during kidney development, but of these only Wnt11 can result in transformation (Christiansen et al., 1996) and b-catenin accumulation (Ku and Melton, 1993) . Curiously, human Wnt3 and Wnt15 have both been mapped to within 125 kb on human chromosome 17q21 (Bergstein et al., 1997) , a region identi®ed as a familial Wilms' tumour gene, FWT1 (Rahman et al., 1998) , although their expression in kidney has not been investigated. Wnt3 does appear to signal via the b-catenin pathway and result in transformation (Shimizu et al., 1997) .
While a subset of WT1 mutant patients display male genital anomalies (Little and Wells, 1997) , female genital anomalies are not associated with WT1 mutation. However, Wnt4 has also been implicated in the normal development of the female genital tract, with Wnt4 7/7 mice displaying a lack of Mullerian ducts, enhanced production of testosterone and masculinization of the Wolan ducts (Vainio et al., 1999) . This does not ®t well with a model in which WT1 activates Wnt4, unless this activation is restricted to the kidney during the MET. This is possible given the example of the speci®c interaction between WT1 and SF1 in the regulation of MIS in the developing male urogenital tract (Nachtigal et al., 1998) . Containing 20 of the 26 published putative WT1 target genes between them, the expression pro®ling performed using these arrays revealed expression of 12 of these genes (Table 1) . Upregulation of c-myc expression by 4.5-fold was detected in C2A, indicative of transcriptional repression of c-myc gene by wildtype WT1. While consistent with ®ndings from reporter assay studies (Hewitt et al., 1995) , this result was not con®rmed by the Clontech array analysis. The ornithine decarboxylase (ODC) gene was weakly expressed (ODC was only detectable on the WT array after extensive exposure, see Figure 2b ) and downregulated in C2A on both arrays. This ®nding was essentially contrary to previous ®ndings from in vitro analyses suggesting repression of ODC by WT1 (Moshier et al., 1996; Li et al., 1999) , but the change was less than twofold and in some instances WT1 can activate ODC (Moshier et al., 1996; Li et al., 1999) . The sensitivity of the Wilms' tumour array should be questioned as murine WT1 failed to be detected in either the parental cell line or the C2A transfectant. This was also the experience of Lee et al. (1999) , but suggests that only those genes with signi®cant levels of expression will be detected. In some instances this may more accurately re¯ect a lack of hybridization between human cDNAs and murine probes rather than a true lack of endogenous expression. However, 12 putative target genes were clearly detectable on the Clontech array and no dierential expression was observed. These results suggest either that these are not WT1 targets or that they are only transiently transcriptionally regulated. Alternatively, this may re¯ect the use of the WT1-C transcript as a backbone for the R394W mutation. WT1 isoforms C and D contain the KTS insertion between ZF3 and 4, making them less able to bind DNA and less likely to be regulating at a transcriptional level.
In summary, we have shown that Wnt-4 expression is disrupted in the presence of WT1-C R394W mutant WT1 protein. We have also established that the hWnt4 gene lies between chromosome 1p35.1 and 1p36.23, have characterized the exon-intron boundaries of hWnt-4 and sequenced 12 kb around hWnt4 exon 1, including 9.0 kb of the hWnt4 promoter. While this eect on Wnt4 expression implies a role for WT1 in the regulation of Wnt4 and, in turn, the process of MET during early stages of metanephric kidney development, this may not involve direct transcriptional regulation of Wnt4 by WT1. However, we have con®rmed that levels of Wnt4 message do increase upon the induction of WT1 protein using WT1-A and WT1-D tetracyclineinducible HEK293 cells. Hence, the upregulation of Wnt4 by WT1 is either due to direct regulation of Wnt4 via a region outside of the minimal promoter de®ned here or is an indirect eect, being elicited via the induction of another factor by WT1.
Materials and methods
Expression construct and generation of stable transfectants
A mutant WT1 expression construct, pEF-DM, was cloned containing a 2061 bp XbaI cDNA fragment of WT1-C isoform harbouring the R394W point mutation commonly found in DDS cases driven by the human elongation factor EF-1a gene (Mizushima and Nagata, 1990) . The C1180T mutation was engineered via digestion of the RsrII site (CG'GTCCG) within exon 9 and T4 DNA polymerase treatment in the presence of excess (5 mM) dATP and 106 excess of a wildtype antisense oligomer C46 (5'TGGTCG3') and a mutant sense oligomer C47 (5' GTTTTCCTG 3'), 10 min, 378C. In the absence of dNTPs, the T4 DNA polymerase acted as a 3'-5' exonuclease until reaching the ®rst available A, at which point polymerase activity and exonuclease activity reached equilibrium. Ligation was then performed using T4 DNA ligase. Subclones having incorporated and replicated the introduced mutation were screened using PCR and direct sequencing. M15 cells were grown in Dulbecco Modi®ed Eagle's medium (GIBCO ± BRL), 10% FBS, 10 mM L-glutamine, and 10 mM penicillin-streptavidin. Stable co-transfection of M15 cells with the pEF-DM and pgk-NEO DNAs was performed using LipofecTAMINE TM reagent (GIBCO ± BRL, LIFE Technologies). For M15 transfection, cells were plated at a density of 2610 5 cells/ well in the 6-well tissue culture plates. The ratio of pEF-DM to pgk-NEO used for each transfection was 20 : 1. Selection of stable transfectants was via culture media (DMEM) containing 400 mg/ml geneticin (G418).
HEK283 Tet-On parental cell lines (Clontech) were cultured in DMEM with tetracycline-free fetal bovine serum (GIBCO ± BRL, Australian sourced). These were transfected with pcDNA3-based mammalian expression constructs containing full length murine WT1-A or WT1-D. Stable clones were selected using 250 mg/ml G418 and 0.4 mg/ml puromycin. Cells were induced to produce WT1 by the addition of 1 mg/ml doxycycline for up to 48 h. Western blot analysis was used to verify the onset of WT1 protein production upon doxycycline induction. 
RT ± PCR SNuPE assay
The reverse transcription (RT) ± PCR single nucleotide primer extension assay (SNuPE) (Singer-Sam et al., 1992) was used to verify the presence of the C1180T point mutation in transfectants. Total cellular RNA from M15 and stable transfectants were extracted according to Chomczynski and Sacchi (1987) , ®rst strand cDNA synthesis performed on 1 mg total RNA, 0.2 mg pd(N) 6 (Pharmacia Biotech), 25U MMLV-RT (Boehringer Mannheim), 1 h, 428C. Subsequent PCRampli®cation was performed using PTGA (5' TGGGATGCTGGACTGTCTC-3', exon 10) and number 300 (5' CTACAGCAGTGACAATTTATAC 3', exon 4) primers (see Figure 1a ). PCR conditions: 1 cycle of 1 min at 958C, 1 min at 558C, and 1 min at 728C; then 39 cycles of 30 s at 928C, 1 min at 558C, and 1 min at 728C, followed by a 10 min ®nal extension at 728C. SNuPE was performed on an aliquot of each PCR reaction using the SNuPE-RWF (5' CTTGTCAGCGAAAGTTTTCC 3') primer for a single-cycle of 1 min at 958C, 3 min at 508C, and 1 min at 708C (see Figure 1a ). For each sample this ®nal extension was performed with both a-32 P-dCTP and a-32 P-dTTP separately, thereby testing for the presence of wildtype or mutant transcripts respectively. Products were resolved on a 15% polyacrylamide gel and visualized using autoradiography.
Development of miniarray and array analysis methodology
The WT1 target gene array was generated by dot-blotting cDNA inserts of 94 dierent genes or genomic DNA onto Magna nylon transfer membrane (Category number NJ0HY320FX, MSI-Bresatec). Full details of the content and construction of the array can be seen at http:// www.cmcb.uq.edu.au/pubs/array.html. Brie¯y, cDNA clones were provided by collaborators or acquired as EST clones (Genome System; ATCC). cDNA inserts were excised from vectors by restriction digestion, or ampli®ed by PCR, gel puri®ed and dot-blotted (Bio-Dot Apparatus, BioRad) in accordance with the manufacturer's protocol. Each cDNA dot contained 10 ng per 500 bp cDNA and the genomic DNA dots contained 150 ng DNA. The clones on this array are either human or mouse, although where possible regions were chosen with good homology between the human and mouse orthologs. The mouse Atlas array is fully described at the Clontech website (http://Atlasinfo.clontech.com). Array analysis was carried out according to the protocols described in Clontech Atlas TM cDNA Expression Arrays User Manual (CLONTECH Laboratories, Inc.). Except for a-32 P-dATP (Amersham), all reagents for radioactive labelling and probe puri®cation were provided by CLON-TECH Laboratories. Collected fractions of puri®ed probes were checked via Cerenkow scintillation counting to compare levels of radioactivity, denatured with 0.1 M NaOH/1 mM EDTA, 5 mg of Cot-1 DNA (Clontech), and neutralized with 0.5 M NaH 2 PO 4 (pH 7.0), prior to hybridization on miniarray blots. Hybridization was at 688C for 48 h in ExpressHyb (Clontech) buer. Increasing stringency washes (SSC/SDS) were performed at 658C. Visualization of results was via autoradiography. Quantitation of signal intensities on the autoradiograph was done using densitometric analysis.
Veri®cation using Northern analysis Northern hybridization was performed as previously described (Sambrook et al., 1989) using speci®c probes in question versus GAPDH gene as a control probe. Results were either visualized using autoradiography or phosphoimage analysis. Phosphoimage readings were assessed via the Molecular Imager System (Model GS363, BioRad) and presented using the Molecular Analyst software, Version 2.1 (BioRad).
BLAST sequence search, sequence alignment analysis, and gene mapping
The sequences of full length mouse Wnt-4 cDNA, human ESTs clones similar to mouse Wnt-4, and human Clone 224A6 were obtained from the GenBank database via the National Center for Biotechnology Information (http:// www.ncbi.nlm.nih.gov/). Sequence-match searches were conducted using the BASIC BLAST (BlastN) search engine available at the NCBI website. All sequence alignments were done using the Sequencher TM Version 3.1.1 (Gene Codes Corporation) software. PCR primers designed to putative hWnt4 were veri®ed using human genomic DNA. Ampli®ed DNA fragments were cloned into pGEMT-Easy (Promega), for sequencing. All preparation of DNA samples for automated sequencing were according to the ABI Sequencing protocols (PE Biosystem). Samples were processed by the Australian Genome Research Facilities (AGRF, Brisbane Division, http://www.agrf.org.au).
Isolation of human Wnt-4 genomic clones
The RPCI-1 human genomic PAC library was supplied by Dr Panos Ioannou, Murdoch Institute for Birth Defects, Melbourne (Ioannou et al., 1994) . Superpools were PCR screened using hWNT4-F2 (5'-TCTGAAAAG-CATGGGGTGGG-3') and hWNT-B12 (5'-AACGAACA-CACTCCTTCCAGCCTG-3') primers, which detect a 204 bp 5' region of hWnt-4 intron 1, and HW441-60 (5'-CACCATGAGTCCCCGCTCGT-3') and HW4103-86 (5'GCTGAGAAGACGGCGAAG-3'), which detect a 63 bp region of hWnt-4 exon 1. Positive products were detected in Superpools 224, 229, 284 and 289. Gridded positive primary pools were colony-lifted onto nylon and hybridized as previously described with the 204 bp intron 1 PCR fragment. Clone 289-3.1 was found to contain Wnt4 exon 1 and no other exons.
Human Wnt4 promoter characterization PAC clone 289-3.1, containing hWnt4 exon 1 but not exons 2 ± 5, was initially restriction digested using BamHI, HindIII and EcoRI, Southern blotted and hybridized back to a 63 bp PCR product of Wnt4 exon 1. This probe was generated via standard PCR ampli®cation from the PAC itself using primers HW4.41-60 (5'CACCATGAGTCCCCGCTCGT 3') and HW4.103-86 (5' CGACTCTTCTGCCGCTTC 3'). Subclones covering a total of 9 kb of promoter and 3 kb of intron 1 were subsequently further analysed using restriction digestion and shotgun cloning using common blunt-cutters (SmaI, RsaI, DraII, PvuI) subcloned into SmaI cut pBluescribe (7). Shotgun clones were sequenced as described above and a contig tiling created using the Sequencher TM Version 3.1.1 (Gene Codes Corporation). Gaps in the tiling were covered via the design of new primers, PCR ampli®ca-tion and sequencing. Two larger subclones were generated for the generation of pGL2Basic luciferase constructs. These contained a 9 kb HindIII/NotI promoter region (pGL2BWnt4p9), representing the largest region of Wnt4 promoter analysed, and a SacI/NotI fragment containing 1.2 kb of immediate promoter (pGL2BWnt4p1.2). The 1.2 kb of immediate promoter was analysed for the presence of transcription factor binding sites using the MatInspector V2.2 transcription factor consensus search engine (http:// www.gsf.de/cgi-bin/matsearch.pl, Quandt et al., 1995) . As the WT1 binding site is variable, the same region was searched for the following previously identi®ed WT1-binding consensus sequences: CGCCCCCGC (Rauscher et al., 1990) ; TCCTCCTCC (Wang et al., 1992) ; GNGNGGGNG (Fraizer et al., 1994) ; GCG(T/G)GG-GAG-(T/G)(T/G/A)(T/G) (Hamilton et al., 1995; Nakagama et al., 1995; Borel et al., 1996) ; GGAGAGGGAGGATC (Little et al., 1996) .
Luciferase reporter assays
COS7, M15 and HEK293 WT1-A or WT1-D stable cell lines were grown and transiently transfected as previously described for stable transfection. For COS7 and M15 cells, 250 ng of reporter or pGL2Basic and 750 ng of expression construct or pcDNA3.1 was used for each transfection following optimization via standard curve analysis. Luciferase activity was measured after 48 h by lysing cells in 50 mM HEPES pH 7.9, 1 mM CaCl2 1 mM MgCl2, 2% Triton N-101, 10 min, followed by incubation in Luciferase Assay reagent (Roche). Suspensions were transferred to a 96-well format for quantitation using a Packard Opti-plate microplate luminescence counter. Individual transfection experiments were performed in triplicate and luciferase activity corrected for protein concentration, as assessed via a Lowry assay, and normalized with respect to pGL2Basic. For HEL293 cells, transfection was either accompanied with the addition of doxycycline and cells were harvested 24 h after transfection, or induction was commenced before transient transfection such that doxycycline induction occurred for 48 h.
